Rosario valadares Serrao

Dr. Rosario valadares Serrao


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet
Verified
Journal Article
Closed access
PCPedro Cahn
Pedro Cahn
JMJuan Sierra Madero
Juan Sierra Madero
JAJosé Ramón Arribas
José Ramón Arribas
AAAndrea Antinori
Andrea Antinori
RORoberto Ortiz
Roberto Ortiz
AUAndrew Ustianowski
Andrew Ustianowski


1 February 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
RSRosario valadares Serrao
Rosario valadares Serrao
CPCarmela Piñero
Carmela Piñero
JVJorge Velez
Jorge Velez
DCDaniel Coutinho
Daniel Coutinho
FMFernando Maltez
Fernando Maltez
LPLeonor Pássaro
Leonor Pássaro
To characterize the profile of non-AIDS-related comorbidities (NARC) in the older HIV-1-infected population and to explore the factors associated with multiple NARC. This was a multicentre, cross-sectional study including HIV-1-infected patients aged ≥50 years, who were virologically suppressed and had been on a stable antiretroviral therapy (ART) regimen for at least 6 months. A multiple regression model explored the association between demographic and clinical variables and the number of NARC. Overall, 401 patients were enrolled. The mean age of the patients was 59.3 years and 72.6% were male. The mean duration of HIV-1 infection was 12.0 years and the median exposure to ART was 10.0 years. The mean number of NARC was 2.1, and 34.7% of patients had three or more NARC. Hypercholesterolemia was the most frequent NARC (60.8%), followed by arterial hypertension (39.7%) and chronic depression/anxiety (23.9%). Arterial hypertension and diabetes mellitus were the most frequently treated NARC (95.6% and 92.6% of cases, respectively). The linear regression analysis showed a positive relationship between age and NARC (B=0.032, 95% confidence interval 0.015-0.049; p=0.0003) and between the duration of HIV-1 infection and NARC (B=0.039, 95% confidence interval 0.017-0.059; p=0.0005). A high prevalence of NARC was found, the most common being metabolic, cardiovascular, and psychological conditions. NARC rates were similar to those reported for the general population, suggesting a larger societal problem beyond HIV infection. A multidisciplinary approach is essential to reduce the burden of complex multi-morbid conditions in the HIV-1-infected population.

1 June 2012 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
MRMaribel Rodriguez-Torres
Maribel Rodriguez-Torres
JSJihad Slim
Jihad Slim
LBLaveeza Bhatti
Laveeza Bhatti
RSRichard Sterling
Richard Sterling
MSMark Sulkowski
Mark Sulkowski
SSSaray Stancic
Saray Stancic
Background: The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials. Objective: This randomized, double-blind, international, parallel-group study in specialist outpatient clinics in the United States, Spain, and Portugal compares the efficacy and safety of 2 RBV dose regimens (800 mg/day and 1000/1200 mg/day) combined with peginterferon alfa-2a (40KD) in patients with HIV-HCV (genotype 1) coinfection. Methods: Patients with HIV-HCV coinfec-tion, quantifiable HCV RNA in serum, HCV genotype-1 infection, compensated liver disease, and stable HIV disease (CD4+ count ≥100 cells/µL) with or without ongoing antiretroviral therapy were randomized to 48 weeks’ treatment with RBV at standard dose (800 mg/day) or weight-based dose (1000 mg/day for patients weighing <75 kg; 1200 mg/day for patients weighing ≥75 kg) in combination with peginterferon alfa-2a (40KD) 180 µg once a week. Planned enrollment was 400 patients with ≥100 non-Latino African Americans. The primary endpoint was sustained virological response (SVR) (undetectable HCV RNA [<20 IU/mL] at the end of a 24-week untreated follow-up period [week 72]). Results: SVR rates were 19% (26/135) and 22% (60/275) in patients randomized to RBV 800 mg/day and 1000/1200 mg/day, respectively (odds ratio, 1.15; 95% CI, 0.68–1.93; P = .6119). In the 1000/1200 mg/day RBV dose group, the incidence of hemoglobin reductions <100 g/L and anaemia reported as an adverse event were higher versus the standard 800 mg/day RBV dose group. Conclusions: Compared with the standard RBV dose (800 mg/day), weight-based RBV dosing (1000/1200 mg/day) did not significantly increase SVR rates, but did increase the incidence of anemia in HIV-HCV (genotype 1) coinfected patients.

1 November 2017 in The Lancet HIV
Verified
Journal Article
Closed access
PCPedro Cahn
Pedro Cahn
RKRichard Kaplan
Richard Kaplan
PSPaul E Sax
Paul E Sax
KSKathleen Squires
Kathleen Squires
JMJean-Michel Molina
Jean-Michel Molina
CHCb Hsiao
Cb Hsiao

22 August 2013 in Eurosurveillance
Verified
Journal Article
Open access
LSLurdes Santos
Lurdes Santos
JMJoão Mesquita
João Mesquita
NPN Rocha Pereira
N Rocha Pereira
CLC Lima-Alves
C Lima-Alves
RSRosario valadares Serrao
Rosario valadares Serrao
ASA Sarmento
A Sarmento
Autochthonous hepatitis E virus (HEV) infection has been increasingly reported in Europe and the United States, mostly arising from genotype 3 and less frequently genotype 4. We report here on a patient with HEV genotype 3a infection complicated by Guillain-Barré syndrome in Portugal in December 2012. We draw attention to the diagnosis of autochthonous HEV infection and to its rare, but important, neurological complications. .